By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Astellas Pharma Inc. 

3-11 Nihonbashi-Honcho 2-chome

Chuo-ku  Tokyo  103-8411  Japan
Phone: 81-3-3244-3000 Fax: 81-3-3244-3272




Company News
QIAGEN N.V. (QGEN) Announces Broad Agreement With Astellas Pharma Inc. (ALPMY) To Develop Companion Diagnostics 10/29/2014 7:32:23 AM
Astellas Pharma Inc. (ALPMY)'s XTANDI™ (Enzalutamide) Capsules Receive Positive CHMP Opinion For The Treatment Of Men With Metastatic Castration-Resistant Prostate Cancer Who Are Chemotherapy-Naïve 10/24/2014 10:58:35 AM
Astellas Pharma Inc. (ALPMY), CoMentis, Inc. Terminate Alzheimer's Agreement 10/17/2014 6:24:11 AM
Astellas Pharma Inc. (ALPMY) Announces Research Collaboration With Harvard Medical School Investigator For Treatment Of Retinal Degeneration 10/14/2014 8:14:55 AM
Astellas Pharma Inc. (ALPMY) Presents New Findings For Isavuconazole In Mucormycosis At IDWeek 10/8/2014 8:33:13 AM
Astellas Pharma Inc. (ALPMY) Launches New Employee Benefits Program In Response To Multi-Generational Family Needs 10/3/2014 7:22:28 AM
Christy Noland To Lead Urology Advocacy And Communications For Astellas Pharma Inc. (ALPMY) 9/17/2014 8:04:46 AM
Medivation, Inc. (MDVN) Banks $90 Million From Astellas Pharma Inc. (ALPMY) As FDA Expands Use Of Prostate Cancer Drug 9/11/2014 9:15:46 AM
Astellas Pharma Inc. (ALPMY) Release: U.S. FDA Approves New Indication For The Use Of XTANDI® (enzalutamide) Capsules For Patients With Metastatic Castration-Resistant Prostate Cancer 9/11/2014 7:16:16 AM
Astellas Pharma Inc. (ALPMY) Receives Notification From FDA Of Acceptance Of Filing Of Isavuconazole NDA For The Treatment Of Invasive Aspergillosis And Invasive Mucormycosis 9/8/2014 7:28:28 AM